Abstract
New drug innovation and the strategy to combat antibiotic resistance mechanisms Updated Quarterly
Introduction:This report reviews new drug innovation and strategy to
combat antibiotic resistance mechanisms. This embraces current research-stage
activities, patents published in the last five years, the entire
pharmaceutical development pipeline and today' s existing armoury of
anti-bacterial drugs. The report reviews around 400+ pipeline antibiotics and
anti-bacterial technologies (from pre-clinical to Phase III/initial launch),
350+ antibiotic patents published between Jan 2002 and Jan 2008 and more than
200 fully launched antibiotics. It identifies and discusses new antibiotics,
technologies and strategies at the anti-bacterial mechanistic level, that are
specifically being developed to combat resistance mechanisms. The
opportunities which they potentially offer in tackling the increasing global
threat of antibiotic resistance, are discussed.
Overview: This report gives a comprehensive and detailed review of
pipeline, emerging and current antibiotics and anti-bacterial technologies and
their potential to provide more effective long-term therapies. More than 900
drugs, drug candidates and developmental compounds are identified, discussed
and classified on the basis of their mode of action, developmental stage,
activities and capabilities and by companies and research groups responsible
for taking these activities forward. Moreover, they are considered in terms of
their importance and potential to combat resistant pathogens, as part of the
global effort to find alternatives to current antibiotics, which have lost or
are losing their effectiveness against common and serious pathogens. The
report looks in depth at current developments and thinking on how antibiotic
resistance can be tackled technically and strategically, from improvements to
existing drugs and drug combinations, to novel molecules, new and more
promising drug targets and approaches to tackling resistance at its source.
More detailed information on this report is given in the printable Report
Description, which is linked to this page.
Combating Antibiotic Resistance: This review examines more than 370
pipeline candidates and 340 antibiotic patents, published between Jan 2002 and
Jan 2008. These patents were selected from more than 1800 patents citing
"anti-infectives", published over the same period. Strategies being developed
to combat resistance mechanisms include the identification of new selective
targets, the selection of targets which may preclude genomic/phenotypic
adaptation by bacteria, or where this is considered more difficult, combined
activity molecules, molecules which inhibit stress-induced mutational
emergence of resistance genes in response to synthetic antibiotics, novel
antibacterial technologies, new targeting strategies and synthetic or
semi-synthetic approaches vs. drugs of natural origin. Other areas reviewed
include virulence targeting, the dissemination of adaptable traits, predicting
resistance and the developing importance of pathogenomics.
View Cart
